Faurholt-Jepsen M, Brage S, Vinberg M, Christensen EM, Knorr U, Jensen HM, et al
FDA therefore identified a theoretical carcinogenic concern where chronic exposure activates telomerase or extends telomeres in cells capable of malignant transformation
The promise of GLP-1s to address these concerns is understandably appealing, but we lack adequate research to guide evidence-based prescribing and patient decisionmaking for this population
Until these substances go through properly controlled studies in human volunteers, nobody can say with any confidence how a given body will respond.
Several transcripts have been proposed to play a role in the development of GD but their exact mechanism of action, and their utility for clinical care are unclear (140-142)